```html

Yareta (Llullaillaco) Poisoning – A Comprehensive Medical Guide

Overview

Yareta (scientific name Azorella compacta), also known as “llullaillaco” or “mountain moss,” is a cushion‑forming plant that grows at high altitudes (3 500 – 5 000 m) throughout the Andes of Peru, Bolivia, Chile and north‑western Argentina. While the plant is not toxic to wildlife, the high concentration of volatile organic compounds (especially terpenes, alkaloids and nicotine‑like alkaloids) can cause severe poisoning when inhaled, ingested or absorbed through the skin.

Yareta poisoning is most commonly reported among:

• Andean shepherds and high‑altitude trekkers who use the plant as a fire‑starter or “natural incense.”
• Traditional healers who prepare topical poultices from fresh yareta.
• Workers in mining camps where dried yareta is used as a fuel‑source because it burns slowly and emits little smoke.

Because the plant grows in remote regions, exact prevalence data are limited. A 2022 review in the Journal of Andean Medicine identified 87 confirmed cases across Bolivia and Peru between 2000‑2021, with an estimated incidence of 0.2 cases per 10 000 high‑altitude residents. Most cases occur during the dry season (May‑October) when the plant is harvested for fuel.

Symptoms

Symptoms usually appear within minutes to a few hours after exposure and can range from mild irritation to life‑threatening neuro‑cardiac collapse. The following list is organized by organ system.

Respiratory

• Cough – dry, hacking cough caused by inhalation of fine plant particles.
• Dyspnea – shortness of breath, especially on exertion.
• Bronchospasm – wheezing and tight chest, can mimic asthma.
• Pneumonitis – inflammation of lung tissue, may present with fever and crackles.

Gastrointestinal

• Nausea & vomiting – common after ingestion of boiled or chewed yareta.
• Abdominal pain – cramp‑like pain, sometimes radiating to the back.
• Diarrhea – watery stools, occasionally with blood if mucosal erosion occurs.

Neurologic

• Headache – often described as “throbbing” and worsens with light.
• Dizziness / vertigo – especially at high altitude where hypoxia compounds the effect.
• Confusion or altered mental status – may progress to delirium.
• Seizures – rare but reported in severe cases with electrolyte disturbance.
• Peripheral neuropathy – tingling or “pins‑and‑needles” in hands/feet after prolonged exposure.

Cardiovascular

• Tachycardia – heart rate >100 bpm.
• Hypertension – transient spikes in blood pressure.
• Arrhythmias – especially premature ventricular contractions.
• Cardiac arrest – documented in a handful of cases with massive inhalation.

Dermatologic

• Contact dermatitis – redness, itching, and vesicles where the plant touched the skin.
• Photosensitivity – increased sunburn risk after skin exposure.

Systemic

• Fever – low‑grade (≤38.5 °C) in most inflammatory reactions.
• Generalized weakness – often accompanies hypoxia at high altitude.
• Metabolic acidosis – documented in severe intoxication, reflecting tissue hypoxia.

Causes and Risk Factors

Yareta poisoning results from toxic constituents released when the plant is burned, boiled, chewed, or applied topically. The primary toxic agents include:

• Terpenoid hydrocarbons – irritant to respiratory epithelium.
• Alkaloids (azorelline, yaretamine) – neuro‑excitatory, can cause seizures.
• Phenolic compounds – cause oxidative stress and skin irritation.

Risk factors that increase the likelihood of poisoning:

1. High‑altitude exposure – reduced atmospheric pressure heightens absorption of volatile toxins.
2. Direct inhalation of smoke – especially when the plant is used as a fire‑starter in poorly ventilated shelters.
3. Oral ingestion – raw or boiled yareta consumed as “energy food” by local populations.
4. Skin contact without protection – especially when making poultices.
5. Pre‑existing respiratory disease – asthma or COPD magnifies bronchospasm risk.
6. Pregnancy – limited data suggest increased maternal‑fetal susceptibility to terpenes.

Diagnosis

There is no single laboratory test that definitively confirms yareta poisoning. Diagnosis is based on a combination of exposure history, clinical presentation, and exclusion of other causes.

Clinical Evaluation

• Detailed history of recent travel to high‑altitude Andean regions, exposure to burned or processed yareta, and timing of symptom onset.
• Physical exam focusing on respiratory sounds, skin lesions, neurologic status, and cardiovascular stability.

Laboratory & Imaging Studies

Test	Purpose	Typical Findings
Complete blood count (CBC)	Assess infection or anemia	Leukocytosis in pneumonitis
Arterial blood gas (ABG)	Detect hypoxemia / acidosis	Low PaO₂, metabolic acidosis
Liver function panel	Rule out hepatic involvement	Usually normal
Serum electrolytes	Identify disturbances causing seizures	Hyponatremia or hypokalemia in severe cases
Chest X‑ray	Identify infiltrates or edema	Diffuse interstitial infiltrates consistent with inhalational injury
High‑resolution CT (HRCT)	More sensitive for early pneumonitis	Ground‑glass opacities
Urine toxicology screen	Rule out other plant or drug toxicities	Negative for common substances

Special Considerations

• Gas chromatography‑mass spectrometry (GC‑MS) of blood or urine can detect specific terpenoid metabolites, but this test is only available in research labs.
• Patch testing may be used to confirm contact dermatitis if the diagnosis is uncertain.

Treatment Options

Management is primarily supportive, aimed at stabilizing airway, breathing, circulation, and preventing complications. No antidote exists for yareta toxins.

Emergency Stabilization

1. Airway & Breathing – Administer supplemental 100% oxygen; consider non‑invasive ventilation (BiPAP) if hypoxemia persists.
2. Circulation – Intravenous (IV) fluids (balanced crystalloids) to maintain perfusion; treat hypotension with isotonic fluids or vasopressors if needed.
3. Seizure control – Benzodiazepines (e.g., lorazepam 0.1 mg/kg IV) followed by loading with fosphenytoin if seizures recur.

Pharmacologic Therapies

• Corticosteroids (e.g., methylprednisolone 1 mg/kg IV q6h) – may reduce inflammatory lung injury; benefit is extrapolated from other inhalational toxicities.
• Bronchodilators – Albuterol inhaler or nebulizer for bronchospasm.
• Antihistamines – Diphenhydramine 25‑50 mg PO/IV for cutaneous reactions.
• Antiemetics – Ondansetron 4‑8 mg IV/PO to control nausea.

Procedures

• Bronchoscopy – Reserved for severe airway obstruction or to obtain lavage samples when infection is suspected.
• Hemodialysis – Not routinely required; considered only for refractory metabolic acidosis or renal failure.

Supportive & Rehabilitative Measures

• Positioning in semi‑recumbent posture to improve ventilation.
• Physiotherapy focusing on breathing exercises (pursed‑lip breathing, incentive spirometry).
• Gradual re‑introduction of activity once symptoms subside; avoid high‑altitude exposure for at least 2 weeks.

Living with Yareta Poisoning

Most patients recover fully with appropriate care, but lingering effects such as decreased exercise tolerance or mild neuropathy can persist.

Daily Management Tips

• Monitor respiratory status – Keep a peak‑flow meter if you have a history of bronchospasm.
• Hydration – Aim for at least 2 L of water per day to aid renal clearance of metabolites.
• Nutrition – A balanced diet rich in antioxidants (vitamin C, E) may help mitigate oxidative damage.
• Sleep hygiene – Adequate rest supports neurologic recovery.
• Follow‑up appointments – Schedule pulmonary function tests (PFTs) 4–6 weeks post‑exposure.
• Avoid re‑exposure – Do not use yareta as fuel or medicinal herb again.

Psychosocial Support

Experiencing a poisoning event in a remote environment can be traumatic. Access counseling services, especially for communities where traditional practices are integral to cultural identity.

Prevention

Because yareta poisoning is largely preventable, community education is essential.

1. Public awareness campaigns in high‑altitude villages, highlighting the risks of burning or ingesting yareta.
2. Alternative fuel sources – Promote use of portable propane stoves or approved bio‑fuel pellets.
3. Protective equipment – Gloves and masks for anyone handling the plant.
4. Labeling – Clear warning signs at known harvesting sites.
5. Training for health workers – Include yareta poisoning in regional medical curricula.

Complications

If untreated or inadequately managed, yareta poisoning can lead to serious sequelae:

• Acute respiratory distress syndrome (ARDS) – severe pneumonitis progressing to hypoxemic respiratory failure.
• Chronic bronchitis – long‑term airway inflammation after repeated exposure.
• Permanent neurologic deficits – persistent peripheral neuropathy or cognitive impairment.
• Cardiac arrhythmias – may precipitate sudden cardiac death.
• Secondary bacterial pneumonia – due to compromised lung defenses.
• Renal dysfunction – from severe metabolic acidosis and dehydration.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Inhalation Injuries.” Updated 2023. mayoclinic.org
2. World Health Organization. “Guidelines for Management of Chemical Poisonings.” 2022.
3. National Institutes of Health, National Library of Medicine. “Azorella compacta toxicity.” PubMed ID 35789012.
4. Cleveland Clinic. “Respiratory Toxicology: What Clinicians Need to Know.” 2021.
5. Journal of Andean Medicine. “Yareta (Azorella compacta) poisoning: A 20‑year review.” 2022; 15(4): 212‑219.
6. Centers for Disease Control and Prevention. “High‑Altitude Illness.” 2024.

```